ACRS logo

Aclaris Therapeutics Inc. (ACRS)

$3.38

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on ACRS

Market cap

$536109064

EPS

-0.58

P/E ratio

--

Price to sales

68.55

Dividend yield

--

Beta

0.976138

Price on ACRS

Previous close

$3.61

Today's open

$3.47

Day's range

$3.32 - $3.56

52 week range

$2.34 - $6.60

Profile about ACRS

CEO

Neal Walker

Employees

73

Headquarters

Wayne, PA

Exchange

Nasdaq Global Select

Shares outstanding

158612149

Issue type

Common Stock

ACRS industries and sectors

Healthcare

Biotechnology & Life Sciences

News on ACRS

This Aclaris Therapeutics Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

news source

Benzinga • Nov 17, 2026

news preview

Aclaris Therapeutics Announces Top Line Phase 2 Results for its Anti-TSLP Monoclonal Antibody Bosakitug (ATI-045) in Atopic Dermatitis (AD)

- The ADMIRATION Trial Did Not Achieve its Primary Endpoint of Percent Change in Eczema Area and Severity Index (EASI) Score from Baseline at Week 24 - - Aclaris Remains Focused on Prioritizing the Development of its Oral Kinase (ITK) Inhibitors and Anti-TSLP/IL-4Rα Bispecific Antibody ATI-052 - WAYNE, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced top line results from the Phase 2 ADMIRATION trial that evaluated the efficacy and safety of bosakitug (ATI-045), a humanized anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody, in patients with moderate-to-severe atopic dermatitis.

news source

GlobeNewsWire • Nov 16, 2026

news preview

Aclaris Therapeutics, Summit Therapeutics And Other Big Stocks Moving Lower In Monday's Pre-Market Session

U.S. stock futures were lower this morning, with the Nasdaq 100 futures falling over 1% on Monday.

news source

Benzinga • Nov 16, 2026

news preview

Why is Aclaris Therapeutics Stock Trading Lower on Monday?

Aclaris Therapeutics Inc. (NASDAQ:ACRS) CEO Neal Walker affirmed on Monday that the clinical-stage biopharmaceutical company will maintain its core development priorities despite missing primary and secondary endpoints in a Phase 2 atopic dermatitis study.

news source

Benzinga • Nov 16, 2026

news preview

Aclaris Therapeutics Initiates Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus (LP)

- Dual Inhibition of ITK and JAK3 Provides Potential for Modzatinib to be the First Mechanistically Complete Oral Therapy for Lichen Planus, an Unaddressed Inflammatory Disease with No Approved Therapeutic Options - - Unique Mechanism Targets Key Pathways Implicated in LP Pathology, T-cell Receptor Signaling Upstream and Effector Cytokine Signaling Downstream - WAYNE, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced initiation of its randomized, double-blind, placebo-controlled Phase 2b ALPHA trial of modzatinib (ATI-2138) in patients with moderate-to-severe lichen planus (LP); the first cohort to be enrolled will be patients with oral erosive lichen planus (OLP).

news source

GlobeNewsWire • Nov 16, 2026

news preview

Aclaris Therapeutics to Participate in the Jefferies Global Healthcare Conference

WAYNE, Pa., Nov. 12, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced that on Monday November 16 at 10:30 AM GMT (5:30 AM ET), Aclaris' Chief Executive Officer Dr. Neal Walker and other members of Aclaris' senior leadership team will participate in a fireside chat during the Jefferies Global Healthcare Conference in London, UK. A live and archived webcast of this event will be accessible on the Events page of the Aclaris website, www.aclaristx.com.

news source

GlobeNewsWire • Nov 12, 2026

news preview

Aclaris Therapeutics Reports Third Quarter 2026 Financial Results and Provides Corporate and Clinical Update

- Initiation of Phase 2b Trial of Modzatinib (ATI-2138) in Lichen Planus Expected in Fourth Quarter of 2026 - - Timeline Reaffirmed for Top Line Results from Phase 2 ADMIRATION Trial of Bosakitug (ATI-045) in Atopic Dermatitis (AD) - - Positive Primary Analysis Results Announced from Phase 1b Proof-of-Concept (POC) Trials of ATI-052 in AD and Asthma - - Strong Cash Runway Expected to Enable Development of Pipeline Through the First Half of 2029 - WAYNE, Pa., Nov. 05, 2026 (GLOBE NEWSWIRE) -- Aclaris Therapeutics, Inc. (NASDAQ: ACRS), a clinical-stage biopharmaceutical company focused on developing novel product candidates for immuno-inflammatory diseases, today announced its financial results for the third quarter of 2026 and provided a corporate and clinical update.

news source

GlobeNewsWire • Nov 5, 2026

news preview

Aclaris Therapeutics (ACRS) Reports Q3 Loss, Beats Revenue Estimates

Aclaris Therapeutics (ACRS) came out with a quarterly loss of $0.12 per share versus the Zacks Consensus Estimate of a loss of $0.16. This compares to a loss of $0.12 per share a year ago.

news source

Zacks Investment Research • Nov 5, 2026

news preview

Aclaris Therapeutics ATI-052 Posts Early Eczema, Asthma Signals in Phase 1b

Aclaris Therapeutics NASDAQ: ACRS reported Phase 1b proof-of-concept results for ATI-052, its bispecific antibody designed to inhibit thymic stromal lymphopoietin (TSLP) and IL-4 receptor alpha, in small studies of atopic dermatitis and asthma. The company said the treatment was well tolerated and produced early clinical and biomarker signals in both indications.

news source

MarketBeat • Oct 27, 2026

news preview

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript

Aclaris Therapeutics, Inc. (ACRS) Discusses ATI-052 Proof-of-Concept Results in Atopic Dermatitis and Asthma Transcript

news source

Seeking Alpha • Oct 27, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Aclaris Therapeutics Inc.

Open an M1 investment account to buy and sell Aclaris Therapeutics Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in ACRS on M1